LAG3 anticorps (full length)

N° du produit ABIN7878542

Cet anticorps Souris Monoclonal détecte spécifiquement LAG3 dans ELISA. Il présente une réactivité avec des échantillons de Humain.

Aperçu rapide pour LAG3 anticorps (full length) (ABIN7878542)

Antigène: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp LAG3 est non-conjugé

Application: ELISA

Classe de qualité: Carrier-free

Clone: LAG3-3261

Détail du produit anti-LAG3 anticorps

Épitope: full length

Fonction: LAG3 Antibody / Lymphocyte activation gene 3 / CD223 (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogène: A recombinant full-length human LAG3 protein was used as the immunogen for this LAG3 antibody.

Isotype: IgG2a, kappa

Information d'application

Indications d'application: Optimal dilution of the LAG3 antibody should be determined by the researcher.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Agent conservateur: Azide free

Stock: 4 °C,-20 °C

Stockage commentaire: Store the LAG3 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Détails sur LAG3

Antigène: LAG3 (Lymphocyte-Activation Gene 3 (LAG3))

Autre désignation: LAG3

Sujet: LAG-3 (also called CD223) is a high affinity MHC class II ligand present on the surface of CD4+CD8+ T cells and NK cell, with shared homology in structure to CD4 Molecules. It has a glutamic acid-proline (EP) repetitive sequence found in other functionally distinct mammalian, parasitic, and bacterial proteins that may influence a conserved biological function. LAG-3+CD4+CD8+ T cells can associate with the T cell receptor (TCR) and downregulate TCR signaling in vitro. LAG-3 inhibits CD4-dependent T cell function via its cytoplasmic domain. LAG-3 Lys-468 within a conserved 'KIEELE' motif is essential for interaction with downstream signaling molecules. Furthermore, as a checkpoint inhibitor target, it may be superior to CTLA-4 and PD-1 since both antibodies only activate effector T-cells, whereas an antagonist LAG-3 antibody can both activate T effector cells (by downregulating the LAG-3 inhibiting signal into pre-activated LAG-3+ cells) and inhibit induced (i.e. antigen-specific) Treg suppressive activity.

UniProt: P18627

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints